Loading...
•
Sep 30, 2020
Fate Therapeutics Q3 2020 Earnings Report
Fate Therapeutics reported third quarter 2020 financial results and highlighted operational progress.
Key Takeaways
Fate Therapeutics reported revenue of $7.6 million for the third quarter of 2020, derived from collaborations with Janssen and Ono Pharmaceutical. The company's cash, cash equivalents, and investments totaled $502.0 million as of September 30, 2020.
First patients treated with dual-antigen targeting regimen of FT596 in combination with Rituximab for B-cell Lymphoma.
FT596 Phase 1 Study Expanded to Include Chronic Lymphocytic Leukemia.
First Patient Treated with FT516 in Combination with Avelumab for Advanced Solid Tumors.
Enrollment Initiated with FT538, the First CRISPR-edited, iPSC-derived Cell Therapy, for Acute Myeloid Leukemia and Multiple Myeloma.
Revenue by Segment
Forward Guidance
Fate Therapeutics plans to initiate a multi-center Phase 1 clinical trial of FT819 in the fourth quarter of 2020.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...